Supernus Pharmaceuticals’ (SUPN) “Buy” Rating Reiterated at Mizuho

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reiterated by research analysts at Mizuho in a report issued on Wednesday, AnalystRatings.com reports. They presently have a $63.00 price objective on the specialty pharmaceutical company’s stock. Mizuho’s price objective suggests a potential upside of 66.45% from the stock’s current price.

The analysts wrote, “We believe the Day failed to rally SUPN because of the cautious body language around the SPN-810 asset in impulsive aggression. We believe investors may avoid the pending Phase III SPN-810 impulsive aggression read-out in 2H:19 (next big catalyst/clearing event for the stock) because mgmt. highlighted the pioneering aspects of its program, and its unprecedented reliance on daily caregiver data reports. We reiterate our Buy rating as SUPN trades below our $47 bear case valuation which assigns no value to SPN-810.””

A number of other brokerages have also commented on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $46.00 price target for the company in a research note on Saturday, March 2nd. B. Riley set a $65.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 4th. Cantor Fitzgerald set a $57.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 10th. ValuEngine lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, Piper Jaffray Companies set a $44.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, January 16th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $55.75.

Shares of SUPN stock opened at $37.85 on Wednesday. Supernus Pharmaceuticals has a 52 week low of $30.05 and a 52 week high of $61.25. The company has a market capitalization of $1.97 billion, a PE ratio of 18.46 and a beta of 1.59. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.06 and a quick ratio of 2.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.21. Supernus Pharmaceuticals had a net margin of 27.14% and a return on equity of 27.45%. The firm had revenue of $113.50 million during the quarter, compared to analyst estimates of $105.36 million. During the same period in the previous year, the business posted $0.26 earnings per share. The business’s revenue for the quarter was up 31.4% on a year-over-year basis. Equities research analysts anticipate that Supernus Pharmaceuticals will post 2.37 EPS for the current fiscal year.

In other news, CFO Gregory S. Patrick sold 20,000 shares of the business’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $41.53, for a total value of $830,600.00. Following the transaction, the chief financial officer now owns 67,896 shares of the company’s stock, valued at $2,819,720.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.20% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Menta Capital LLC increased its position in Supernus Pharmaceuticals by 3.5% in the fourth quarter. Menta Capital LLC now owns 7,824 shares of the specialty pharmaceutical company’s stock worth $260,000 after purchasing an additional 265 shares during the last quarter. Victory Capital Management Inc. increased its position in Supernus Pharmaceuticals by 4.1% in the fourth quarter. Victory Capital Management Inc. now owns 7,536 shares of the specialty pharmaceutical company’s stock worth $250,000 after purchasing an additional 296 shares during the last quarter. Advisor Group Inc. increased its position in Supernus Pharmaceuticals by 17.2% in the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 306 shares during the last quarter. Campbell Newman Asset Management Inc. increased its position in Supernus Pharmaceuticals by 2.5% in the first quarter. Campbell Newman Asset Management Inc. now owns 16,567 shares of the specialty pharmaceutical company’s stock worth $581,000 after purchasing an additional 397 shares during the last quarter. Finally, Mizuho Securities USA LLC increased its position in Supernus Pharmaceuticals by 3.4% in the fourth quarter. Mizuho Securities USA LLC now owns 12,000 shares of the specialty pharmaceutical company’s stock worth $399,000 after purchasing an additional 400 shares during the last quarter. 99.18% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit